{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:55:41Z","timestamp":1779270941142,"version":"3.51.4"},"reference-count":56,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2021,10,12]]},"abstract":"<jats:p>Background: Epigenetic changes may contribute importantly to cognitive decline in late life including Alzheimer\u2019s disease (AD) and vascular dementia (VaD). Bromodomain and extra-terminal (BET) proteins are epigenetic \u201creaders\u201d that may distort normal gene expression and contribute to chronic disorders. Objective: To assess the effects of apabetalone, a small molecule BET protein inhibitor, on cognitive performance of patients 70 years or older participating in a randomized trial of patients at high risk for major cardiovascular events (MACE). Methods: The Montreal Cognitive Assessment (MoCA) was performed on all patients 70 years or older at the time of randomization. 464 participants were randomized to apabetalone or placebo in the cognition sub-study. In a prespecified analysis, participants were assigned to one of three groups: MoCA score\u226526 (normal performance), MoCA score 25\u201322 (mild cognitive impairment), and MoCA score\u226421 (dementia). Exposure to apabetalone was equivalent in the treatment groups in each MoCA-defined group. Results: Apabetalone was associated with an increased total MoCA score in participants with baseline MoCA score of\u226421 (p\u200a=\u200a0.02). There was no significant difference in change from baseline in the treatment groups with higher MoCA scores. In the cognition study, more patients randomized to apabetalone discontinued study drug for adverse effects (11.3% versus 7.9%). Conclusion: In this randomized controlled study, apabetalone was associated with improved cognition as measured by MoCA scores in those with baseline scores of 21 or less. BET protein inhibitors warrant further investigation for late life cognitive disorders.<\/jats:p>","DOI":"10.3233\/jad-210570","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T14:14:23Z","timestamp":1629814463000},"page":"1703-1715","source":"Crossref","is-referenced-by-count":26,"title":["Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial"],"prefix":"10.1177","volume":"83","author":[{"given":"Jeffrey","family":"Cummings","sequence":"first","affiliation":[{"name":"Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV), Las Vegas, NV, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory G.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Colorado School of Medicine, Aurora, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Victorian Heart Institute, Monash University, Melbourne, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aziz","family":"Khan","sequence":"additional","affiliation":[{"name":"Resverlogix Corporation, Calgary, AB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Halliday","sequence":"additional","affiliation":[{"name":"Resverlogix Corporation, Calgary, AB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[{"name":"Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Sweeney","sequence":"additional","affiliation":[{"name":"Resverlogix Corporation, Calgary, AB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan O.","family":"Johansson","sequence":"additional","affiliation":[{"name":"Resverlogix Corporation, Calgary, AB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norman C.W.","family":"Wong","sequence":"additional","affiliation":[{"name":"Resverlogix Corporation, Calgary, AB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewelina","family":"Kulikowski","sequence":"additional","affiliation":[{"name":"Resverlogix Corporation, Calgary, AB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamyar","family":"Kalantar-Zadeh","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, University of California Irvine, Irvine, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Lebioda","sequence":"additional","affiliation":[{"name":"Resverlogix Corporation, Calgary, AB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry N.","family":"Ginsberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bengt","family":"Winblad","sequence":"additional","affiliation":[{"name":"Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden"},{"name":"Karolinska University Hospital, Theme Inflammation and Aging, Huddinge, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, M\u00f6lndal, Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M\u00f6lndal, Sweden"},{"name":"UK Dementia Research Institute at UCL, London, UK"},{"name":"Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[{"name":"Imperial Centre for Cardiovascular Disease Prevention, Imperial College, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-210570_ref1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1474-4422(18)30403-4","article-title":"Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"GBD 2016 Dementia Collaborators","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-210570_ref2","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/j.jacc.2020.03.053","article-title":"Associations between cardiovascular risk, structural brain changes, and cognitive decline","volume":"75","author":"Song","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.3233\/JAD-210570_ref3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12916-014-0130-5","article-title":"Cardiovascular risk factors and future risk of Alzheimer\u2019s disease","volume":"12","author":"de Brujin","year":"2014","journal-title":"BMC Med"},{"key":"10.3233\/JAD-210570_ref4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2337\/ds16-0041","article-title":"Type 2 diabetes, cognition, and dementia in older adults: Toward a precision health approach","volume":"29","author":"Cholerton","year":"2016","journal-title":"Diabetes Spectrum"},{"key":"10.3233\/JAD-210570_ref5","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3233\/JAD-150980","article-title":"Unraveling Alzheimer\u2019s: Making sense of the relationship between diabetes and Alzheimer\u2019s disease","volume":"51","author":"Schilling","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-210570_ref6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s11011-020-00561-y","article-title":"Association between chronic kidney disease and Alzheimer\u2019s disease: An update","volume":"35","author":"Zhang","year":"2020","journal-title":"Metab Brain Dis"},{"key":"10.3233\/JAD-210570_ref7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.diabres.2016.10.024","article-title":"An updated meta-analysis of cohort studies: Diabetes and risk of Alzheimer\u2019s disease","volume":"124","author":"Zhang","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"10.3233\/JAD-210570_ref8","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer\u2019s disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"10.3233\/JAD-210570_ref9","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/bies.20104","article-title":"Lysine acetylation and the bromodomain: A new partnership for signaling","volume":"26","author":"Yang","year":"2004","journal-title":"BioEssays"},{"key":"10.3233\/JAD-210570_ref10","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1161\/CIRCRESAHA.120.315929","article-title":"BET epigenetic reader proteins in cardiovascular transcriptional programs","volume":"126","author":"Borck","year":"2020","journal-title":"Circ Res"},{"key":"10.3233\/JAD-210570_ref11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/med.21730","article-title":"Inhibitors of bromodomain and extra-terminal proteins for treating multiple human diseases","volume":"41","author":"Kulikowski","year":"2021","journal-title":"Med Res Rev"},{"key":"10.3233\/JAD-210570_ref12","doi-asserted-by":"crossref","first-page":"108306","DOI":"10.1016\/j.neuropharm.2020.108306","article-title":"BET bromodomains as novel epigenetic targets for brain health and disease","volume":"181","author":"Singh","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.3233\/JAD-210570_ref13","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1038\/tp.2017.202","article-title":"The BET\/BRD inhibitor JQ1 improves brain plasticity in WT and APP mice","volume":"7","author":"Benito","year":"2017","journal-title":"Transl Psychiatry"},{"key":"10.3233\/JAD-210570_ref14","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2174\/1567205013666160427101832","article-title":"The BET-bromodomain inhibitor JQ1 reduces inflammation and tau phosphorylation at Ser396 in the brain of the 3xTg model of Alzheimer\u2019s disease","volume":"13","author":"Magistri","year":"2016","journal-title":"Cur Alzheimer Res"},{"key":"10.3233\/JAD-210570_ref15","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1038\/nn.4095","article-title":"BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice","volume":"18","author":"Korb","year":"2015","journal-title":"Nat Neurosci"},{"key":"10.3233\/JAD-210570_ref16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ahj.2019.08.001","article-title":"Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial","volume":"217","author":"Ray","year":"2019","journal-title":"Am Heart J"},{"key":"10.3233\/JAD-210570_ref17","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jama.2020.3308","article-title":"Effect of apabetalone added to standard therapy on major adverse cardiovascular events in patients with recent acute coronary syndrome and type 2 diabetes: A randomized clinical trial","volume":"323","author":"Ray","year":"2020","journal-title":"JAMA"},{"key":"10.3233\/JAD-210570_ref18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12933-020-01199-x","article-title":"Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: A prespecified analysis of the BETonMACE study","volume":"20","author":"Nicholls","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.3233\/JAD-210570_ref19","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2215\/CJN.16751020","article-title":"Effect of apabetalone on cardiovascular events in diabetes, CKD, and recent acute coronary syndrome: Results from the BETonMACE randomized controlled trial","volume":"16","author":"Kalantar-Zadeh","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.3233\/JAD-210570_ref20","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"10.3233\/JAD-210570_ref21","doi-asserted-by":"crossref","first-page":"2517658","DOI":"10.1155\/2019\/2517658","article-title":"Responsiveness, minimal clinically important difference, and validity of the MoCA in stroke rehabilitation","volume":"2019","author":"Wu","year":"2019","journal-title":"Occup Ther Int"},{"key":"10.3233\/JAD-210570_ref22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000351864","article-title":"Evidence of the sensitivity of the MoCA alternate forms in monitoring cognitive change in early Alzheimer\u2019s disease","volume":"37","author":"Costa","year":"2014","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.3233\/JAD-210570_ref23","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1017\/S135561771200077X","article-title":"Montreal Cognitive Assessment (MoCA): Validation study for vascular dementia","volume":"18","author":"Freitas","year":"2012","journal-title":"J Int Neuropsychol Soc"},{"key":"10.3233\/JAD-210570_ref24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000329722","article-title":"Alkaline phosphatase is increased in both brain and plasma in Alzheimer\u2019s disease","volume":"9","author":"Vardy","year":"2012","journal-title":"Neurodegenerative Dis"},{"key":"10.3233\/JAD-210570_ref25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.atherosclerosis.2019.09.002","article-title":"Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease","volume":"290","author":"Haarhaus","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.3233\/JAD-210570_ref26","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1212\/WNL.0b013e318230208a","article-title":"Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample","volume":"77","author":"Rossetti","year":"2011","journal-title":"Neurology"},{"key":"10.3233\/JAD-210570_ref27","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2174\/1381612823666170124121140","article-title":"Understanding epigenetic alterations in Alzheimer\u2019s and Parkinson\u2019s disease: Towards targeted biomarkers and therapies","volume":"23","author":"Ciceri","year":"2017","journal-title":"Curr Pharm Des"},{"key":"10.3233\/JAD-210570_ref28","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.arr.2013.05.003","article-title":"Epigenetic mechanisms in Alzheimer\u2019s disease: Implications for pathogenesis and therapy","volume":"12","author":"Wang","year":"2013","journal-title":"Ageing Res Rev"},{"key":"10.3233\/JAD-210570_ref29","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41574-018-0048-7","article-title":"Cognitive decline and dementia in diabetes mellitus: Mechanisms and clinical implications","volume":"14","author":"Biessels","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.3233\/JAD-210570_ref30","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1212\/WNL.0b013e3181f4d7f8","article-title":"Diabetes, Alzheimer disease, and vascular dementia: A population-based neuropathologic study","volume":"75","author":"Ahtiluoto","year":"2010","journal-title":"Neurology"},{"key":"10.3233\/JAD-210570_ref31","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jalz.2015.12.006","article-title":"Diabetes is associated with cerebrovascular but not Alzheimer\u2019s disease neuropathology","volume":"12","author":"Abner","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-210570_ref32","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1474-4422(06)70537-3","article-title":"Risk score for the prediction of dementia risk in 20 years among middle aged people: A longitudinal, population-based study","volume":"5","author":"Kivipelto","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-210570_ref33","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.1997.03540340047031","article-title":"Brain infarction and the clinical expression of Alzheimer disease. The Nun Study","volume":"277","author":"Snowdon","year":"1997","journal-title":"JAMA"},{"key":"10.3233\/JAD-210570_ref34","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neuint.2019.03.004","article-title":"Neuroprotective effects of targeting BET proteins for degradation with dBET1 in aged mice subjected to ischemic stroke","volume":"127","author":"DeMars","year":"2019","journal-title":"Neurochem Int"},{"key":"10.3233\/JAD-210570_ref35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jalz.2017.10.009","article-title":"Forecasting the prevalence of preclinical and clinical Alzheimer\u2019s disease in the United States","volume":"14","author":"Brookmeyer","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-210570_ref36","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13148-020-00943-0","article-title":"BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes","volume":"12","author":"Wasiak","year":"2020","journal-title":"Clin Epigenet"},{"key":"10.3233\/JAD-210570_ref37","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13148-019-0696-z","article-title":"Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism","volume":"11","author":"Tsujikawa","year":"2019","journal-title":"Clin Epigenet"},{"key":"10.3233\/JAD-210570_ref38","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00401-020-02215-w","article-title":"Cerebral blood flow decrease as an early pathological mechanism in Alzheimer\u2019s disease","volume":"140","author":"Korte","year":"2020","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-210570_ref39","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1177\/0271678X19873658","article-title":"Increasing cerebral blood flow improves cognition into late stages in Alzheimer\u2019s disease mice","volume":"40","author":"Bracko","year":"2019","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.3233\/JAD-210570_ref40","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fnagi.2020.00185","article-title":"Dysfunction of the blood-brain barrier\u2014a key step in neurodegeneration and dementia","volume":"12","author":"Noe","year":"2020","journal-title":"Front Aging Neurosci"},{"key":"10.3233\/JAD-210570_ref41","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41586-020-2453-z","article-title":"Physiological blood-brain transport is impaired with age by a shift in transcytosis","volume":"583","author":"Yang","year":"2020","journal-title":"Nature"},{"key":"10.3233\/JAD-210570_ref42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-210570_ref43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbi.2016.03.010","article-title":"The blood-brain barrier in systemic inflammation","volume":"60","author":"Varatharaj","year":"2017","journal-title":"Brain Behav Immun"},{"key":"10.3233\/JAD-210570_ref44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nbd.2016.07.007","article-title":"The blood-brain barrier in Alzheimer\u2019s disease","volume":"107","author":"Zenaro","year":"2017","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JAD-210570_ref45","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3389\/fnagi.2014.00171","article-title":"Systemic inflammation, blood-brain barrier vulnerability and cognitive\/non-cognitive symptoms in Alzheimer disease: Relevance to pathogenesis and therapy","volume":"6","author":"Takeda","year":"2014","journal-title":"Front Aging Neurosci"},{"key":"10.3233\/JAD-210570_ref46","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.bbadis.2015.12.015","article-title":"Vascular cognitive impairment and dementia","volume":"1862","author":"Gorelick","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.3233\/JAD-210570_ref47","unstructured":"Wasiak S , Fu L , Daze E , Gilham D , Rakai BD , Stotz SC , Tsujikawa LM , Sarsons CD , Jahagirdar R , Wong NCW , Sweeney M , Johansson JO , Kulikowski E (2021) The epigenetic modulator apabetalone decreases neuroinflammation in blood brain barrier cell models and LPS-treated mice. CTAD 2021 (abstract accepted for oral presentation)."},{"key":"10.3233\/JAD-210570_ref48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-030-05542-4_2","article-title":"The role of biomarkers in Alzheimer\u2019s disease drug development","volume":"1118","author":"Cummings","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.3233\/JAD-210570_ref49","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13195-019-0529-5","article-title":"The \u201crights\u201d of precision drug development for Alzheimer\u2019s disease","volume":"11","author":"Cummings","year":"2019","journal-title":"Alz Res Therapy"},{"key":"10.3233\/JAD-210570_ref50","first-page":"114","article-title":"Plasma alkaline phosphatase is elevated in Alzheimer\u2019s disease and inversely correlates with cognitive function","volume":"2","author":"Kellett","year":"2011","journal-title":"Int J Mol Epidemiol Genet"},{"key":"10.3233\/JAD-210570_ref51","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40520-020-01572-6","article-title":"Serum alkaline phosphatase is elevated and inversely correlated with cognitive functions in subjective cognitive decline: Results from the ReGAl 2.0 project","volume":"33","author":"Boccardi","year":"2021","journal-title":"Aging Clin Exp Res"},{"key":"10.3233\/JAD-210570_ref52","doi-asserted-by":"crossref","first-page":"e197978","DOI":"10.1001\/jamanetworkopen.2019.7978","article-title":"Association of altered liver enzymes with Alzheimer disease diagnosis, cognition, neuroimaging measures, and cerebrospinal fluid biomarkers","volume":"2","author":"Nho","year":"2019","journal-title":"JAMA Network Open"},{"key":"10.3233\/JAD-210570_ref53","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.atherosclerosis.2018.11.002","article-title":"Apabetalone downregulates factors and pathways associated with vascular calcification","volume":"280","author":"Gilham","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.3233\/JAD-210570_ref54","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00018-016-2320-0","article-title":"BET bromodomain proteins and epigenetic regulation of inflammation: Implications for type 2 diabetes and breast cancer","volume":"74","author":"Nicholas","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"10.3233\/JAD-210570_ref55","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1212\/WNL.0000000000004717","article-title":"Alzheimer\u2019s Disease-Related Dementias Summit 2016: National research priorities","volume":"89","author":"Corriveau","year":"2017","journal-title":"Neurology"},{"key":"10.3233\/JAD-210570_ref56","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3389\/fneur.2018.00701","article-title":"Application of precision medicine in neurodegenerative diseases","volume":"9","author":"Strafella","year":"2018","journal-title":"Front Neurol"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-210570","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:07:05Z","timestamp":1777370825000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-210570"}},"subtitle":[],"editor":[{"given":"Babak","family":"Tousi","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":56,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/jad-210570","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,12]]}}}